Sanofi Net Worth 2010-2024 | SNY

Interactive chart of historical net worth (market cap) for Sanofi (SNY) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Sanofi net worth as of June 19, 2024 is $119.46B.
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $119.456B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $847.248B 122.45
Novo Nordisk (NVO) Denmark $631.845B 48.55
Johnson & Johnson (JNJ) United States $350.533B 13.92
Merck (MRK) United States $324.174B 58.98
AbbVie (ABBV) United States $302.599B 15.64
AstraZeneca (AZN) United Kingdom $243.139B 21.14
Novartis AG (NVS) Switzerland $214.497B 15.21
Pfizer (PFE) United States $155.321B 19.30
Innoviva (INVA) United States $1.013B 7.11